anti-melanoma mab fragments
Various (V09)Various (V09) compound in Provectus Biopharmaceuticals's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
biotech · Melanoma · Psoriasis · PVCT
Provectus Biopharmaceuticals
PROVECTUS BIOPHARMACEUTICALS, INC.
Provectus Biopharmaceuticals drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Knoxville, Tennessee 37932, US HQ
2004 Founded
7 Employees
Public company Type
PVCT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Knoxville, Tennessee 37932, US
- Founded
- 2004
- Employees
- 7
- Programs
- 12
- Drugs
- 5
- Patents
- 29
Provectus Biopharmaceuticals pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Provectus Biopharmaceuticals drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Provectus Biopharmaceuticals in public FDA and regional records.
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Dihydropteroate synthase.
- Target
- Dihydropteroate synthase
- Mechanism
- Bacterial dihydropteroate synthase inhibitor